实用肝脏病杂志 ›› 2025, Vol. 28 ›› Issue (5): 671-674.doi: 10.3969/j.issn.1672-5069.2025.05.008

• 病毒性肝炎 • 上一篇    下一篇

艾米替诺福韦联合鳖甲煎丸治疗慢性乙型肝炎患者疗效初步研究*

汤勤, 华忠, 苏麒麟, 陈小林   

  1. 214005 江苏省无锡市 江南大学附属第五医院/无锡市第五人民医院中西医结合科(汤勤,华忠,苏麒麟);江苏省无锡监狱医院消化科门诊(陈小林)
  • 收稿日期:2025-01-14 出版日期:2025-09-10 发布日期:2025-09-19
  • 作者简介:汤勤,女,47岁,大学本科,主治医师。E-mail:8070157@163.com
  • 基金资助:
    *江苏省科技厅重点研发计划产业前瞻与关键技术项目(编号:BE2021049-1)

A preliminary study on efficacy of tenofovir amibufenamide and Biejiajian pill combination in the treatment of patients with chronic hepatitis B

Tang Qin, Hua Zhong, Su Qilin, et al   

  1. Department of Integrated Traditional Chinese and Western Medicine, Fifth Affiliated Hospital, Jiangnan University, Wuxi214005, Jiangsu Province,China
  • Received:2025-01-14 Online:2025-09-10 Published:2025-09-19

摘要: 目的 研究艾米替诺福韦(TMF)联合鳖甲煎丸治疗慢性乙型肝炎(CHB)患者的疗效。方法 2022年8月~2024年7月我院收治的CHB患者154例,被随机分为对照组77例,给予TMF治疗,和观察组77例,给予TMF联合鳖甲煎丸治疗,在治疗48周评估疗效。采用实时荧光定量PCR法检测血清HBV DNA载量,采用ELISA法检测血清HBsAg和HBeAg、Ⅲ型前胶原(PC-Ⅲ)、IV型胶原(IV-Col)、层黏连蛋白(LN)和透明质酸(HA)和白细胞介素(IL)-6、IL-8、肿瘤坏死因子-ɑ(TNF-ɑ)和超敏C反应蛋白(hs-CRP)。结果 在治疗48周末,两组血清HBV DNA均转阴,观察组血清丙氨酸氨基转移酶水平为(42.4±7.4)IU/L,显著低于对照组【(56.5±9.3)IU/L,P<0.05】;观察组血清PC-Ⅲ、HA和IV-Col水平分别为(112.5±18.3)μg/L、(132.5±17.9)μg/L和(159.7±11.8)μg/L,显著低于对照组【分别为(157.3±21.3)μg/L、(162.9±20.2)μg/L和(197.5±29.2)μg/L,P<0.05】; 观察组血清IL-6、IL-8和TNF-ɑ水平分别为(6.3±1.1)pg/mL、(15.7±6.5)pg/mL和(20.5±9.5)pg/mL,均显著低于对照组【分别为(11.8±2.3)pg/mL、(28.1±9.1)pg/mL和(37.6±8.8)pg/mL,P<0.05】。结论 应用TMF联合鳖甲煎丸治疗CHB患者具有显著的改善肝功能的疗效,在病毒转阴的同时,可能有助于减轻机体炎性反应,抑制肝纤维化进展。

关键词: 慢性乙型肝炎, 艾米替诺福韦, 鳖甲煎丸, 治疗

Abstract: Objective The aim of this study was to investigate clinical efficacy of tenofovir amibufenamide (TMF) and Biejiajian compound, a herbal medicine pill, combination in the treatment of patients with chronic hepatitis B (CHB). Methods A total of154 naïve patients with CHB were enrolled in our hospital between August 2022 and July 2024, and were randomly assigned to receive TMF in 77 cases in the control group or to receive TMF and herbal medicine combination therapy in another 77 cases in the observation group. Serum HBV DNA loads was detected by real-time fluorescence quantitative PCR, serum HBsAg and HBeAg, precollagen type Ⅲ(PC-Ⅲ), collagen type IV(IV-Col), laminin (LN) and hyaluronic acid(HA), and interleukin(IL)-6,IL-8, tumor necrosis factor -ɑ(TNF-ɑ) and high-sensitive C reactive protein (hs-CRP) levels were measured by ELISA. Results By end of 48 week treatment, serum HBV DNA transferred to negative in all the patients with CHB in the two groups, and serum alanine aminotransferase level in the observation group was(42.4±7.4)IU/L, much lower than [(56.5±9.3)IU/L, P<0.05] in the control; serum PC-Ⅲ,HA and IV-Col levels were (112.5±18.3)μg/L, (132.5±17.9)μg/L and (159.7±11.8)μg/L, all significantly lower than [(157.3±21.3)μg/L, (162.9±20.2)μg/L and (197.5±29.2)μg/L, respectively, P<0.05] in the control; serum IL-6, IL-8 and TNF-ɑ levels were (6.3±1.1)pg/mL, (15.7±6.5)pg/mL and (20.5±9.5)pg/mL, all much lower than [(11.8±2.3)pg/mL,(28.1±9.1)pg/mL and (37.6±8.8)pg/mL, respectively, P<0.05] in the control group. Conclusion TMF and Biejiajian pill combination in the treatment of patients with CHB has a satisfactory efficacy, which might inhibit body inflammatory reaction and relieve liver fibrosis.

Key words: CHepatitis B, Tenofovir amibufenamide, Biejiajian pills, herbal medicine, Therapy